Associate

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

Muscular Dystrophy Association’s Funding of Foundational Research Leads to New FDA Approved Treatment Duvyzat (givinostat) for Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, March 21, 2024
HDAC, Gene expression, Cell, Disease, MDA, Associate, Patient, Research, DNA, Public policy, University, Muscular dystrophy, Doctor of Philosophy, Muscular Dystrophy Association, Duchenne muscular dystrophy, Clinical trial, Therapy, Histone deacetylase inhibitor, Stair climbing, Plasma protein binding, FDA, Steroid, DMD, Parent, Lancet, Pediatrics, Human, Food, Pharmaceutical industry

"The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.

Key Points: 
  • "The approval of Duvyzat (givinostat) provides another significant treatment option for people living with Duchenne muscular dystrophy,” said Sharon Hesterlee, PhD, Chief Research Officer, MDA.
  • “Muscular Dystrophy Association’s funding was fundamental for the discovery of HDACi in the treatment of Duchenne muscular dystrophy.
  • “We’re excited to celebrate this additional treatment option for people living with Duchenne muscular dystrophy.
  • My son is an example,” said Jessica Curran, MDA family member and mother of Conner who lives with Duchenne muscular dystrophy.

Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer

Retrieved on: 
Thursday, March 21, 2024
Toxicity, Associate, FACOG, Part, Wayne State University, Patient, MRC, Rest, Peripheral neuropathy, Senior, TSX, Safety, Gynecologic Oncology (journal), Infrared spectroscopy correlation table, FDA, Food, Pharmaceutical industry

The study’s Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol.

Key Points: 
  • The study’s Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and has approved initiation of the next cohort with an increased dose, in accordance with the updated dose optimization protocol.
  • Study centers are now actively recruiting patients for the second cohort, with one patient already enrolled and treated with the higher dose.
  • The dose for the initial six patients was 1.75 mg/kg/dose and the dose for the next cohort of patients is 2.50 mg/kg/dose.
  • Further details about the study design, participation criteria and contact information for the sites can be found at: https://clinicaltrials.gov/study/NCT04706962 .

Rose Hill Partners with University of Guelph for Groundbreaking Study to Advance Research for the Potential Benefits of Psilocybin Mushrooms to Address Autism in the Adolescent Brain

Retrieved on: 
Thursday, March 21, 2024
Psilocybin, University of Guelph, Research, Certification, Brain, Learning, University, Memory, Associate, Partnership, Patient, Knowledge, Fungus, Agriculture, Anxiety, Adolescence, Autism spectrum, Biomedical sciences, Spectrum, ASD, Biomass, Pharmaceutical industry

This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.

Key Points: 
  • This collaboration marks a significant milestone for both entities as they embark on a pioneering exploration of the potential benefits of psilocybin to address autism in the adolescent brain, the first-of-its-kind partnership in this space.
  • The collaborative preclinical research will focus on exploring and standardizing the chemical diversity of Rose Hill’s psilocybin mushrooms, legally imported from Jamaica to Canada for the work.
  • Additionally, utilizing a rodent model, the study will investigate their potential application in Autism Spectrum Disorders (ASD).
  • Psilocybin mushrooms, known for their psychoactive properties, have long captivated the scientific community's interest due to their potential therapeutic applications and unique biochemical composition.

Ensemble Health Partners Recognized for the Third Year in a Row as a Top Workplace for its Commitment to Associate Engagement, Innovation and Work-Life Balance

Retrieved on: 
Wednesday, March 20, 2024
Well, Employment, Culture, Organization, Health, KLAS, Partnership, Recognition, Associate, Research, Health care, Life, Interface (computing), Workplace, HFMA, Curriculum, Ensemble, Human, Management

The Top Workplaces USA Awards are designed to recognize organizations around the country that have cultivated exceptional workplace cultures.

Key Points: 
  • The Top Workplaces USA Awards are designed to recognize organizations around the country that have cultivated exceptional workplace cultures.
  • The awards are a result of an internal, anonymous associate survey conducted by the research firm, Energage.
  • “We are proud to be recognized again as a premier employer of choice for top talent.
  • To search and apply for careers with Ensemble and join a Top Workplace, visit EnsembleHP.com/careers .

Raymond James Financial Names Paul Shoukry President and CEO Successor, Announces Additional Key Leadership Changes

Retrieved on: 
Tuesday, March 19, 2024
Financial management, Chair, Assistant, CFO, University of Georgia, Associate, Bank, Columbia University, Executive Committee, Investment banking, MBA, University, Capital market, Shukri, Raymond James Financial, Management

ST. PETERSBURG, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- The Raymond James Financial (NYSE: RJF) Board of Directors announced today that as part of its multi-year succession planning process, effective immediately, CFO Paul Shoukry is appointed president of Raymond James Financial.

Key Points: 
  • ST. PETERSBURG, Fla., March 19, 2024 (GLOBE NEWSWIRE) -- The Raymond James Financial (NYSE: RJF) Board of Directors announced today that as part of its multi-year succession planning process, effective immediately, CFO Paul Shoukry is appointed president of Raymond James Financial.
  • “Paul has been an exceptional leader and major contributor to Raymond James’ steady growth and financial stability.
  • As part of this change, Raymond James Financial Private Client Group President Scott Curtis will become COO of Raymond James Financial, current Raymond James & Associates CEO Tash Elwyn will become president of the Private Client Group, and Global Equities & Investment Banking President Jim Bunn will become president of the Capital Markets segment.
  • Shoukry started with Raymond James 14 years ago working for Tom James and Paul Reilly in the Assistant to the Chair program.

Dairy Council of California Announces 2024 Let’s Eat Healthy Award Winners

Retrieved on: 
Tuesday, March 19, 2024
Dairy Council of California, Health, California Department, Associate, California State University, School, Agriculture, University of California, Wellness, College, Foodservice, Management

SACRAMENTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, is proud to announce the winners of its fifth annual Let’s Eat Healthy Award.

Key Points: 
  • SACRAMENTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Dairy Council of California, a leader in nutrition education and advocacy, is proud to announce the winners of its fifth annual Let’s Eat Healthy Award.
  • In support of its cause to elevate the health of children and communities through the pursuit of lifelong healthy eating patterns, the Let’s Eat Healthy Initiative is honoring seven California nutrition champions.
  • The impactful efforts of these winners contribute significantly to enhancing nutrition education and promoting access to healthy food across California.
  • “We extend our sincere congratulations to the 2024 Let’s Eat Healthy Award winners and look forward to our continued partnership.”
    To learn more about this year’s Let’s Eat Healthy Award winners, the Let’s Eat Healthy Initiative or how to access free nutrition programs and resources, visit HealthyEating.org .

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, March 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.

CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)

Retrieved on: 
Tuesday, March 19, 2024
College, PI3, Data science, Machine, Deep learning, Therapy, Harvard University, Audit trail, Membrane protein, School, Statistics, Biotechnology, ICR, Electrical engineering, Princeton University, 3D, Dartmouth College, Breast cancer, SAB, Applied science, Drug resistance, Royal, Machine learning, Computer science, Drug discovery, Associate, Royal Society, Intelligence, Research, AKT, Cancer, University, Cancer research, DARPA, Howard Hughes Medical Institute, Drug development, Principal, AstraZeneca, Entrepreneurship, The Institute, Biomarker, Columbia University, Faculty, Saint John's College, Stanford University, Chemical engineering, Medicine, Management

LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.

Key Points: 
  • LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company discovering and developing transformational medicines, today announces the foundation of its Scientific Advisory Board (SAB) to provide expert insight and guidance to the Company on the optimal application of 3D deep learning, protein design and prediction in real world medicine.
  • This pioneering technology enables CHARM to target and develop treatments for previously hard-to-drug targets in cancer and other therapeutic areas.
  • Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “As CHARM advances its 3D deep learning platform in discovery it’s critical to maintain aligned oversight of our priorities and keep abreast of this emerging field.
  • Founding members of CHARM’s SAB:
    David Baker, Ph.D. is a Scientific Co-Founder at CHARM and Chair of the SAB.